Six regimens for the eradication of Helicobacter pylori (Hp) in duodenal ulcer patients: Three consecutive trials (1995-1999)

Gy M. Buzás, G. Illyés, E. Székely, I. Széles

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Aim: to present our experience in eradicating Hp in three consecutive trials performed between 1995 and 1999. Methods: 320 duodenal ulcer outpatients have been enrolled in three open, prospective controlled trials. Hp infection was confirmed by Giemsa stain and Rut. In Trial I, 52 cases received 20 mg omeprazole + 2×250 mg clarithromycin + 2×500 mg tinidazole (OCT), 48 patients were given 20 mg omeprazole, 2×1000 mg amoxicillin + 2×500 mg metronidazole (OAM) for 7 days; in Trial II, 48 cases received 40 mg pantoprazole + 2×1000 mg amoxicillin + 2×500 mg clarithromycin (PAC) for 7 days and 51 cases 2×400 mg ranitidin bismuth citrate + 2×500 mg clarithromycin for 14 days (RBC-C); in Trial III, 60 cases were treated with 2×30 mg lansoprazole + 2×250 mg clarithromycin + 2×500 mg metronidazole and 61 patients received 2×400 mg ranitidin bismuth citrate + 2×250 mg clarithromycin + 2×500 mg metronidazole (RBC-CM). The patients were controlled within 4-6 weeks by endoscopy in trials I-II and 13C-urea breath test in trial III. Results: Eradication rates on ITT/PP basis were: OCT: 72.3/80.2% vs OAM 51.2/63.5% (P=0.02/P=0.03); PAC: 80.8/88.3% vs RBC-C 80.3/85.4% (P=0.65/0.67) and LCM 78.3/92.1% vs RBC-CM 78.7/90.5% (P=0.86/P=0.93). Side effects occurred in 5.2, 8.6, 9.5, 14.5, 13.5 and 18.3% of the cases. Conclusion: Regimens using 2×1 PPI or RBC+2 antibiotics for 1 week proved to be the most effective for Hp eradication in duodenal ulcer patients.

Original languageEnglish
Pages (from-to)437-441
Number of pages5
JournalJournal of Physiology Paris
Volume95
Issue number1-6
DOIs
Publication statusPublished - 2001

Fingerprint

Clarithromycin
Duodenal Ulcer
Helicobacter pylori
Metronidazole
Ranitidine
Omeprazole
Amoxicillin
Azure Stains
Tinidazole
Lansoprazole
Breath Tests
Helicobacter Infections
Endoscopy
Urea
Outpatients
Anti-Bacterial Agents
bismuth tripotassium dicitrate

Keywords

  • Antibiotics
  • Duodenal ulcer
  • Eradication
  • Helicobacter pylori

ASJC Scopus subject areas

  • Neuroscience(all)
  • Physiology (medical)

Cite this

Six regimens for the eradication of Helicobacter pylori (Hp) in duodenal ulcer patients : Three consecutive trials (1995-1999). / Buzás, Gy M.; Illyés, G.; Székely, E.; Széles, I.

In: Journal of Physiology Paris, Vol. 95, No. 1-6, 2001, p. 437-441.

Research output: Contribution to journalArticle

@article{500222d567e249178ebfeb21914c37aa,
title = "Six regimens for the eradication of Helicobacter pylori (Hp) in duodenal ulcer patients: Three consecutive trials (1995-1999)",
abstract = "Aim: to present our experience in eradicating Hp in three consecutive trials performed between 1995 and 1999. Methods: 320 duodenal ulcer outpatients have been enrolled in three open, prospective controlled trials. Hp infection was confirmed by Giemsa stain and Rut. In Trial I, 52 cases received 20 mg omeprazole + 2×250 mg clarithromycin + 2×500 mg tinidazole (OCT), 48 patients were given 20 mg omeprazole, 2×1000 mg amoxicillin + 2×500 mg metronidazole (OAM) for 7 days; in Trial II, 48 cases received 40 mg pantoprazole + 2×1000 mg amoxicillin + 2×500 mg clarithromycin (PAC) for 7 days and 51 cases 2×400 mg ranitidin bismuth citrate + 2×500 mg clarithromycin for 14 days (RBC-C); in Trial III, 60 cases were treated with 2×30 mg lansoprazole + 2×250 mg clarithromycin + 2×500 mg metronidazole and 61 patients received 2×400 mg ranitidin bismuth citrate + 2×250 mg clarithromycin + 2×500 mg metronidazole (RBC-CM). The patients were controlled within 4-6 weeks by endoscopy in trials I-II and 13C-urea breath test in trial III. Results: Eradication rates on ITT/PP basis were: OCT: 72.3/80.2{\%} vs OAM 51.2/63.5{\%} (P=0.02/P=0.03); PAC: 80.8/88.3{\%} vs RBC-C 80.3/85.4{\%} (P=0.65/0.67) and LCM 78.3/92.1{\%} vs RBC-CM 78.7/90.5{\%} (P=0.86/P=0.93). Side effects occurred in 5.2, 8.6, 9.5, 14.5, 13.5 and 18.3{\%} of the cases. Conclusion: Regimens using 2×1 PPI or RBC+2 antibiotics for 1 week proved to be the most effective for Hp eradication in duodenal ulcer patients.",
keywords = "Antibiotics, Duodenal ulcer, Eradication, Helicobacter pylori",
author = "Buz{\'a}s, {Gy M.} and G. Illy{\'e}s and E. Sz{\'e}kely and I. Sz{\'e}les",
year = "2001",
doi = "10.1016/S0928-4257(01)00060-2",
language = "English",
volume = "95",
pages = "437--441",
journal = "Journal de Physiologie",
issn = "0928-4257",
publisher = "Elsevier Masson SAS",
number = "1-6",

}

TY - JOUR

T1 - Six regimens for the eradication of Helicobacter pylori (Hp) in duodenal ulcer patients

T2 - Three consecutive trials (1995-1999)

AU - Buzás, Gy M.

AU - Illyés, G.

AU - Székely, E.

AU - Széles, I.

PY - 2001

Y1 - 2001

N2 - Aim: to present our experience in eradicating Hp in three consecutive trials performed between 1995 and 1999. Methods: 320 duodenal ulcer outpatients have been enrolled in three open, prospective controlled trials. Hp infection was confirmed by Giemsa stain and Rut. In Trial I, 52 cases received 20 mg omeprazole + 2×250 mg clarithromycin + 2×500 mg tinidazole (OCT), 48 patients were given 20 mg omeprazole, 2×1000 mg amoxicillin + 2×500 mg metronidazole (OAM) for 7 days; in Trial II, 48 cases received 40 mg pantoprazole + 2×1000 mg amoxicillin + 2×500 mg clarithromycin (PAC) for 7 days and 51 cases 2×400 mg ranitidin bismuth citrate + 2×500 mg clarithromycin for 14 days (RBC-C); in Trial III, 60 cases were treated with 2×30 mg lansoprazole + 2×250 mg clarithromycin + 2×500 mg metronidazole and 61 patients received 2×400 mg ranitidin bismuth citrate + 2×250 mg clarithromycin + 2×500 mg metronidazole (RBC-CM). The patients were controlled within 4-6 weeks by endoscopy in trials I-II and 13C-urea breath test in trial III. Results: Eradication rates on ITT/PP basis were: OCT: 72.3/80.2% vs OAM 51.2/63.5% (P=0.02/P=0.03); PAC: 80.8/88.3% vs RBC-C 80.3/85.4% (P=0.65/0.67) and LCM 78.3/92.1% vs RBC-CM 78.7/90.5% (P=0.86/P=0.93). Side effects occurred in 5.2, 8.6, 9.5, 14.5, 13.5 and 18.3% of the cases. Conclusion: Regimens using 2×1 PPI or RBC+2 antibiotics for 1 week proved to be the most effective for Hp eradication in duodenal ulcer patients.

AB - Aim: to present our experience in eradicating Hp in three consecutive trials performed between 1995 and 1999. Methods: 320 duodenal ulcer outpatients have been enrolled in three open, prospective controlled trials. Hp infection was confirmed by Giemsa stain and Rut. In Trial I, 52 cases received 20 mg omeprazole + 2×250 mg clarithromycin + 2×500 mg tinidazole (OCT), 48 patients were given 20 mg omeprazole, 2×1000 mg amoxicillin + 2×500 mg metronidazole (OAM) for 7 days; in Trial II, 48 cases received 40 mg pantoprazole + 2×1000 mg amoxicillin + 2×500 mg clarithromycin (PAC) for 7 days and 51 cases 2×400 mg ranitidin bismuth citrate + 2×500 mg clarithromycin for 14 days (RBC-C); in Trial III, 60 cases were treated with 2×30 mg lansoprazole + 2×250 mg clarithromycin + 2×500 mg metronidazole and 61 patients received 2×400 mg ranitidin bismuth citrate + 2×250 mg clarithromycin + 2×500 mg metronidazole (RBC-CM). The patients were controlled within 4-6 weeks by endoscopy in trials I-II and 13C-urea breath test in trial III. Results: Eradication rates on ITT/PP basis were: OCT: 72.3/80.2% vs OAM 51.2/63.5% (P=0.02/P=0.03); PAC: 80.8/88.3% vs RBC-C 80.3/85.4% (P=0.65/0.67) and LCM 78.3/92.1% vs RBC-CM 78.7/90.5% (P=0.86/P=0.93). Side effects occurred in 5.2, 8.6, 9.5, 14.5, 13.5 and 18.3% of the cases. Conclusion: Regimens using 2×1 PPI or RBC+2 antibiotics for 1 week proved to be the most effective for Hp eradication in duodenal ulcer patients.

KW - Antibiotics

KW - Duodenal ulcer

KW - Eradication

KW - Helicobacter pylori

UR - http://www.scopus.com/inward/record.url?scp=0034748529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034748529&partnerID=8YFLogxK

U2 - 10.1016/S0928-4257(01)00060-2

DO - 10.1016/S0928-4257(01)00060-2

M3 - Article

C2 - 11595472

AN - SCOPUS:0034748529

VL - 95

SP - 437

EP - 441

JO - Journal de Physiologie

JF - Journal de Physiologie

SN - 0928-4257

IS - 1-6

ER -